|
|
|
|
Direct Cost |
Indirect Cost |
|
| 1DP1CA290976-01A1 |
Immune drivers of oncogenic virus progression to cancer in people living with HIV |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$350,000 |
$194,250 |
$544,250 |
| 1R01CA288372-01A1 |
Targeting Disease Specific Tn Antigen in Pancreatic Cancer |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$117,777 |
$0 |
$117,777 |
| 1R01CA295693-01 |
Porcine Platforms For Technology Development In Pancreatic Cancer |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$414,169 |
$221,580 |
$635,749 |
| 1R03CA297351-01 |
Silencing B7-H3 mitigates tumor aggressiveness in group 3 medulloblastoma |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$50,000 |
$26,750 |
$76,750 |
| 1R21CA297629-01A1 |
Co-targeting IGF-1R and Glutaminase in Ewing Sarcoma |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$257,125 |
$134,061 |
$391,186 |
| 1R21CA298918-01 |
Flupirtine Analogue Synthesis and Screening for the Treatment of Chemotherapy-Induced Neuropathic Pain |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$116,875 |
$62,528 |
$179,403 |
| 1R50CA305093-01 |
Novel Models and Biorepository For Early Detection And Therapeutic Intervention Of Pancreatic Cancer |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$63,391 |
$33,914 |
$97,305 |
| 2T32CA009476-34 |
Cancer Biology Training Program |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$253,752 |
$16,482 |
$262,981 |
| 3F99CA294241-01S1 |
Tumor-cell intrinsic and extrinsic determinants of drug resistance and metastasis |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$3,000 |
|
$3,000 |
| 3P30CA036727-39S1 |
Buffett Cancer Center Support Grant |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$125,000 |
$66,875 |
$191,875 |
| 3P30CA036727-39S2 |
Tracking and Engaging Disconnected Long-Term Survivors of Childhood Cancer to Improve Adherence to Evidence-Based Screening Guidelines |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$65,146 |
$34,853 |
$99,999 |
| 3P30CA036727-39S3 |
Assessing Capacity to Address Obesity for Cancer Prevention and Control |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$62,744 |
$33,568 |
$96,312 |
| 3R01CA273349-04S1 |
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$74,330 |
$39,766 |
$114,096 |
| 3R01CA276846-03S1 |
Preventing invasive prostate cancer |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$90,042 |
$48,172 |
$138,214 |
| 4R01CA273226-04 |
Targeting PKR-Bcl2 Signaling to Overcome Paclitaxel Resistance in Ovarian Cancer |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$573,661 |
$306,909 |
$880,570 |
| 4R01CA273319-04 |
Connectivity mapping identified novel combination therapy for glioblastoma |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$581,000 |
$310,835 |
$891,835 |
| 4R01CA273349-04 |
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$720,580 |
$307,815 |
$1,028,395 |
| 4R01CA274605-04 |
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$457,500 |
$244,762 |
$702,262 |
| 4R01CA276846-03 |
Preventing invasive prostate cancer |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$1,047,132 |
$560,216 |
$1,607,348 |
| 5F30CA268766-03 |
Molecular control of tumor-initiating cells in Ras-driven cancers |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
NCI |
$39,529 |
|
$39,529 |